Merck's acquisition of OncoImmune enriches COVID-19, Oncology and Autoimmune business strategy. Merck (NYSE: MRK) continues to advance another year of competitive transformation with its latest announcement that it is acquiring Rockville, Maryland-based OncoImmune for $425 million plus additional payments based on sales and new product development regulator achievements.
FDA Issues Regeneron's Novel Monoclonal Antibody REGEN-COV2 Emergency Use Authorization To Treat COVID-19
The US Food and Drug Administration (FDA) has issued an emergency use authorization to Regeneron (NASDAQ: REGEN) for its antibody therapy REGEN-COV2 to treat patients diagnosed with COVID-19 that are deemed to be high-risk patients with mild to moderate disease symptoms. REGEN-COV2 is available by prescription only and administered by IV infusion into the bloodstream and triggers an immune response to the COVID-19 infection.
The Health Resources & Services Administration (HRSA) has designated 11/15-2/21 National Rural Health Week. It focuses on the leadership, innovation and challenges that rural medical professionals and their healthcare provider organizations embrace everyday to fulfill their care mission. A pivotal day of focus is Thursday, 11/19 which is designated as National Rural Health Day.
Numerous events reflect the diverse, mission-critical aspects of patient care in rural and remote communities
As expected, Amazon (NASDAQ: AMZN) has unveiled a national prescription drug delivery service and pharmacy benefit program. Known as Amazon Pharmacy, customers will be able to order their prescriptions through Amazon and have them delivered. Through the launch of the Amazon Pharmacy program, Amazon is committing itself to invest and operate in a highly competitive and regulated sector shared by drugstore chains, mass merchandisers, pharmacy benefit managers (PBMs) and managed care organ...
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Eli Lilly's investigational monoclonal antibody therapy (mAb) bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
The U.S. Food and Drug Administration (FDA) has approved NightWare, Inc.’s new Apple Watch and Apple iPhone technology solution indicated for the temporary reduction of sleep disturbance related to nightmares in adults 22 years or older who suffer from nightmare disorder or have nightmares from post-traumatic stress disorder (PTSD). Founded in 2015, NightWare is based in the Minneapolis community of Hopkins. It employs less than 100 staff members and is privately held. One of its financial su...
Diabetes drug and patient care leader Novo Nordisk (NYSE: NVO) has announced it is acquiring Emipshere Technologies (OTCMKTS: EMIS) for $1.8 billion. The deal involves paying $1.35 billion for the company plus taking over about $450 million in royalty payments. Based in Roseland, New Jersey, Emisphere Technologies was founded in 1986. It specializes in the development of technologies and drug delivery systems that enable injectable therapies to be administered orally without changing their ch...
Merck (NYSE: MRK) and Sanofi (NASDAQ: SNY) are committing oncology compounds and other resources to explore the development of new cancer therapy tandems. The leading project in the partnership involves the combined or coordinated administration of Merck’s Keytruda (pembrolizumab) and Sanofi’s non-alpha IL-2 candidate (not FDA-approved at this time) THOR-707 therapy in patients diagnosed with specific types of cancer.
The basic elements of successful healthcare email marketing campaigns
Healthcare marketing professionals are continuing to use more digital assets to promote products and services in support of sales efforts. As this digital trend sustains itself as the pandemic progresses, digital venues are getting more crowded by the minute and this includes email marketing channels. If your email marketing results are plateauing or dropping, start with the basics to boost performance.
Plans have been revealed for two of the largest healthcare systems in the Western United States to merge. Sioux Falls, South Dakota-based Sanford Health and Intermountain Healthcare, headquartered in Salt Lake City, Utah are moving forward with plans to join their respective organizations into one operating entity. The merger of the two healthcare provider organizations is one of the most distinct reflections to date of the ongoing consolidation underway in the hospital sector across the nation.
Bayer builds up its gene therapy enterprise with $4 billion Ask Bio acquisition
Bayer is acquiring Askepios BioPharmaceutical (also referred to as “Ask Bio”) for $2 billion. Ask Bio is a biotechnology firm with a U.S. headquarters in Research Triangle Park, North Carolina and a European headquarters in Edinburgh, Scotland. Founded in 2001, Ask Bio is privately held.
Announcing positive news in the global fight against COVID-19, the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.
Boston-based Atea Pharmaceuticals and Roche have formed a partnership to drive the clinical and commercial development of an oral antiviral agent intended to treat COVID-19. Atea is the innovator of the compound. Roche (OTCQX: RHHBY) now holds exclusive research, development, marketing and sales rights to the product outside of the United States. Atea was paid $350 million upfront and there is potential for them to earn more revenue based on the compound's advancement through clinical trials ...
Email marketing is widely known to be an effective way of reaching medical professionals, patients and consumers. Its primary weaknesses are overuse, incomplete preparation, poor design and lackluster content. Healthcare product manufacturers and service companies, patient care provider organizations and other healthcare interests deploying email marketing can easily optimize their initiatives.
Biotech and pharmaceutical innovator Seattle Genetics (NASDAQ: SGEN) is rebranding itself; its new name is "Seagen". Founded in 1998, Seagen has excelled at specializing in the development and commercialization of monoclonal antibody-based (mAb) therapies for use in oncology including bladder cancer, breast cancer and Hodgkin lymphoma. Its present product portfolio is highly differentiated and...